What You'll Learn
Table of Contents
How Common Is It?
This does not need estimating. Three of the STEP trials were pooled specifically to quantify gastrointestinal tolerability, and constipation was reported by roughly one in four participants on semaglutide 2.4 mg against roughly one in nine on placebo.
Note the placebo number. Some of what people attribute to the medication happens during any period of reduced food intake — but the difference between the arms is real and is caused by the drug.
Pooling STEP 1–3 (semaglutide 2.4 mg, n=2,117; placebo, n=1,262), the most reported gastrointestinal events were nausea (43.9% vs 16.1%), diarrhoea (29.7% vs 15.9%), vomiting (24.5% vs 6.3%) and constipation (24.2% vs 11.1%). 99.5% of events were non-serious and 98.1% mild-to-moderate, occurring most often during or shortly after dose escalation.
PubMed PMID: 34514682 ↗Bottom line: About a quarter of people get it, almost all of it mild-to-moderate and transient, concentrated around dose escalation. It is common, expected, and usually not a reason to stop.
Why The Mechanism Causes It
GLP-1 receptor agonists slow gastric emptying. That is not a side effect bolted onto the drug — it is part of how the drug produces satiety. Slower transit through the gut means more time for water to be reabsorbed from stool, which makes it harder.
Two behavioural changes stack on top of the pharmacology:
- You eat less, so you take in less fibre. Stool volume falls with food volume.
- You drink less. A large share of daily fluid arrives with meals. Smaller meals means less fluid, often without anyone noticing.
That is why the fix is rarely one thing. The cause is three things.
Fibre: More Is Not Automatically Better
Fibre is the obvious lever and the one most often pulled wrong. Adding a large dose of fibre to a gut that is already emptying slowly, without increasing fluid at the same time, can make bloating and discomfort worse rather than better.
The sequence that makes sense given the mechanism:
- Fix fluid first.
- Increase fibre gradually, from food where possible.
- Give each change several days before judging it.
The nutrition guide covers how fibre fits alongside the protein target, which takes priority when appetite is limited.
Movement And Routine
Physical activity increases colonic motility. This is not a dramatic intervention, but it is free, it compounds with everything else you are doing on the medication, and it overlaps with the training you should be doing anyway to protect lean mass.
Consistency of timing matters too. The gut responds to routine, and erratic meal timing on a suppressed appetite works against it.
When To Stop Self-Managing
Ordinary constipation on a GLP-1 is common and self-limiting. Some presentations are not ordinary, and the distinction matters because a small number of serious gastrointestinal events have been documented in this drug class.
In 5,411 people prescribed a GLP-1 for weight loss, compared with bupropion–naltrexone, adjusted hazard ratios were 9.09 (95% CI 1.25–66.00) for pancreatitis, 4.22 (1.02–17.40) for bowel obstruction and 3.67 (1.15–11.90) for gastroparesis. Biliary disease was not significantly raised (1.50, 0.89–2.53). The intervals are wide because these events are rare.
PubMed PMID: 37796527 ↗Important: Severe or worsening abdominal pain, persistent vomiting, abdominal distension, or an inability to pass stool or gas are not constipation to manage at home. Seek medical care. Bowel obstruction and gastroparesis are rare but documented in this drug class, and the symptoms overlap with ordinary side effects at the start.
